2/5
07:00 am
sgmt
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
High
Report
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
2/3
08:03 am
sgmt
Sagimet Biosciences (NASDAQ:SGMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.
Medium
Report
Sagimet Biosciences (NASDAQ:SGMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.
2/3
08:00 am
sgmt
Sagimet Biosciences (NASDAQ:SGMT) is now covered by analysts at Guggenheim. They set a "buy" rating and a $27.00 price target on the stock.
Medium
Report
Sagimet Biosciences (NASDAQ:SGMT) is now covered by analysts at Guggenheim. They set a "buy" rating and a $27.00 price target on the stock.
2/2
07:00 am
sgmt
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
High
Report
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
1/30
08:41 am
sgmt
Sagimet's Denifanstat: China Phase III Safety Data Isn't A Negative Signal [Seeking Alpha]
High
Report
Sagimet's Denifanstat: China Phase III Safety Data Isn't A Negative Signal [Seeking Alpha]
1/29
07:41 am
sgmt
Sagimet Biosciences (NASDAQ:SGMT) was upgraded by analysts at Barclays PLC to a "hold" rating.
Low
Report
Sagimet Biosciences (NASDAQ:SGMT) was upgraded by analysts at Barclays PLC to a "hold" rating.
1/29
06:00 am
sgmt
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
High
Report
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
1/29
06:00 am
sgmt
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
High
Report
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
1/27
07:02 pm
sgmt
Sagimet Biosciences (NASDAQ:SGMT) was given a new $8.00 price target on by analysts at Barclays PLC.
Medium
Report
Sagimet Biosciences (NASDAQ:SGMT) was given a new $8.00 price target on by analysts at Barclays PLC.
1/9
06:11 am
sgmt
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference [Yahoo! Finance]
Medium
Report
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference [Yahoo! Finance]
1/8
07:00 am
sgmt
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
Low
Report
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
12/23
07:03 pm
sgmt
We're Hopeful That Sagimet Biosciences (NASDAQ:SGMT) Will Use Its Cash Wisely [Yahoo! Finance]
Low
Report
We're Hopeful That Sagimet Biosciences (NASDAQ:SGMT) Will Use Its Cash Wisely [Yahoo! Finance]
12/19
02:43 pm
sgmt
Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market [Seeking Alpha]
Medium
Report
Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market [Seeking Alpha]
12/18
07:32 am
sgmt
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination [Yahoo! Finance]
Medium
Report
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination [Yahoo! Finance]
12/18
07:00 am
sgmt
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
Medium
Report
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
12/17
07:56 am
sgmt
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet's Fixed Dose Combination Program [Yahoo! Finance]
Low
Report
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet's Fixed Dose Combination Program [Yahoo! Finance]
12/17
07:00 am
sgmt
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
Medium
Report
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
12/10
07:39 am
sgmt
Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration [Yahoo! Finance]
Low
Report
Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration [Yahoo! Finance]
12/10
07:03 am
sgmt
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
Low
Report
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
12/10
04:15 am
sgmt
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
Low
Report
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
12/10
04:15 am
sgmt
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
Low
Report
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
12/9
04:15 pm
sgmt
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
12/9
04:05 pm
sgmt
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/22
02:11 am
sgmt
Sagimet Biosciences (NASDAQ:SGMT) was downgraded by analysts at
Wall Str
Low
Report
Sagimet Biosciences (NASDAQ:SGMT) was downgraded by analysts at
Wall Str
11/22
02:11 am
sgmt
Sagimet Biosciences (NASDAQ:SGMT) was downgraded by analysts at
Wall Str
Low
Report
Sagimet Biosciences (NASDAQ:SGMT) was downgraded by analysts at
Wall Str